ARVN Arvinas Inc.

50.78
-0.13  -0%
Previous Close 50.91
Open 50.62
Price To Book 14.76
Market Cap 1,979,214,229
Shares 38,976,255
Volume 221,441
Short Ratio
Av. Daily Volume 426,531
Stock charts supplied by TradingView

NewsSee all news

  1. Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference

    NEW HAVEN, Conn., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief

  2. Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors

    NEW HAVEN, Conn., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that Laurie Smaldone Alsup,

  3. Arvinas, Inc. Announces Pricing of Public Offering of Common Stock

    NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the pricing of an

  4. Arvinas, Inc. Announces Proposed Offering of Common Stock

    NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it is commencing an

  5. Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    NEW HAVEN, Conn., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 initial data presented October 23, 2019. Further data due 1H 2020.
ARV-110
Castration-resistant prostate cancer (CRPC)
Phase 1 initial data presented October 23, 2019. Further data due 2H 2020.
ARV-471
ER+ positive / HER2- negative breast cancer

Latest News

  1. Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference

    NEW HAVEN, Conn., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief

  2. Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors

    NEW HAVEN, Conn., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that Laurie Smaldone Alsup,

  3. Arvinas, Inc. Announces Pricing of Public Offering of Common Stock

    NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the pricing of an

  4. Arvinas, Inc. Announces Proposed Offering of Common Stock

    NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it is commencing an

  5. Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    NEW HAVEN, Conn., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial

  6. Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders

    -Data from initial cohorts suggest that Arvinas' PROTAC® platform has the potential to create safe and well-tolerated orally bioavailable drugs for the treatment of certain cancers -Conference call to be held at 8:30 AM

  7. Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders

    NEW HAVEN, Conn., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced that six new thought leaders will

  8. Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio

    - Oerth Bio to utilize Arvinas' PROTAC® technology to develop innovative new agricultural products to improve crop yields- John Dombrosky Announced as CEO of Oerth Bio - Transaction had been formally closed on July 15,